FDA Brief

Warning letters Drugs

FDA warning letter to

Spirochaete Research Labs, LLC aka Scitus Laboratory Products

High riskIssued Mar 8, 2024Posted Mar 12, 2024Center for Drug Evaluation and Research | CDER

FDA warned Spirochaete Research Labs that its Atomic Rhino smelling-salt products are unapproved and misbranded stimulant drugs.

What happened

FDA based the letter on a review of the company's product labels, website (atomicrhino.com), and social media, including Instagram. FDA found four Atomic Rhino smelling-salt products labeled with stimulant claims such as "explosive energy and focus" and directions for intranasal use. FDA says the products contain ammonium chloride, ammonium hydroxide, sodium polyacrylate and/or sodium carbonate and are unapproved new drugs and misbranded.

What FDA found

  1. The four products are unapproved new drugs because no FDA-approved application is in effect for them.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a)
  2. The products are misbranded because they are nonprescription drugs subject to section 505G but do not meet its marketing requirements and lack an approved application.

    section 502(ee) of the FD&C Act, 21 U.S.C. 352(ee)
  3. FDA treats ammonia smelling salts labeled as reflex stimulants as not generally recognized as safe and effective under a 2008 proposed rule, so these products are deemed new drugs.

    section 505G(a)(4) of the FD&C Act, 21 U.S.C. 355h(a)(4); 73 FR 34895
  4. Even as general stimulants, the products do not meet OTC Monograph M011 because they use ammonium hydroxide or ammonium chloride and intranasal directions, which M011 does not cover.

    section 505G of the FD&C Act, 21 U.S.C. 355h; OTC Monograph M011
  5. FDA found no adequate and well-controlled clinical trials supporting that the products are generally recognized as safe and effective for their labeled uses.

    section 505(a) of the FD&C Act, 21 U.S.C. 355(a)

What FDA wants

FDA asks the company to notify it in writing within 15 working days of steps taken to address the violations, explain how recurrence will be prevented, and include supporting documents; if more time is needed, state why and when correction will be completed.

Who should pay attention

  • retailers and online marketplaces selling smelling salts
  • brands that market ammonia inhalants as over-the-counter stimulants
  • distributors of unapproved over-the-counter drug products

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. New Green Nutrition Inc.

    FDA says New Green Nutrition sold unapproved drugs online, and its Qu Feng Huo Luo Dan contained hidden dexamethasone.

    High risk
  2. Ong Tien USA LLC

    FDA warned Ong Tien USA LLC that its herbal joint products are unapproved drugs and one contained hidden piroxicam and dexamethasone.

    High risk
  3. Bella’s Nutri Shop Inc.

    Bella’s Nutri Shop sells “Tawon Liar” as an unapproved drug with hidden dexamethasone, tapentadol, and meloxicam.

    High risk
  4. Jing Cheong Asia Inc. dba New York Tong Ren Tang

    New York Tong Ren Tang marketed unapproved new drugs, including eye drops, on its website.

    High risk